Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack Provides the most potent bactericidal ability that no other PEP antibiotics in ...
TONABACASE, the first registered INN by WHO for Endolysin First-in-Class Endolysin-based Drug against Superbugs US FDA Phase 2 IND Approval for TONABACASE, SAL200 Roivant has returned the rights for ...
SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and ...
iNtRON stated that following the proprietary development of the Robot Bacteriophage 2 nd generation technology, additional in-vitro evolution technology was applied. The Company previously secured the ...
The MarketWatch News Department was not involved in the creation of this content. -- Gram-negative bacterial infections are becoming an increasingly serious global health issue -- U.S. patent ...
Development of Bacteriophages targeting strains causing urinary tract infections Establishment of collaboration with the US Army and investigation of groundwork for entering the US defense market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results